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Abstract
Objectives Despite improved survival due to new treatments, the 10-year survival rate in patients with breast cancer is approximately
75%. Lymphovascular invasion (LVI), a prognostic marker independent from histological grade and stage, can only be fully deter-
mined at final histological examination. Lipid composition is deregulated in tumour via de novo lipogenesis, with alteration in lipogenic
genes in LVI.We hypothesise alteration in lipid composition derived from novel non-invasive spectroscopymethod is associated with
LVI positivity.
Methods Thirty female patients (age 39–78) with invasive ductal carcinomawere enrolled, with 13 LVI negative and 17 LVI positive.
Saturated, monounsaturated, polyunsaturated fatty acids and triglycerides (SFA, MUFA, PUFA and TRG) were quantified from
ex vivo breast tumours freshly excised from patients on a 3 T clinical MRI scanner, and proliferative activity marker Ki-67 and
serotonin derived histologically.
Results There were significantly lower MUFA (p = 0.0189) in LVI positive (median: 0.37, interquartile range (IQR): 0.25–0.64) than
negative (0.63, 0.49–0.96). There were significantly lower TRG (p = 0.0226) in LVI positive (1.32, 0.95–2.43) than negative (2.5,
1.92–4.15). There was no significant difference in SFA (p = 0.6009) or PUFA (p = 0.1641). There was no significant correlation
between lipid composition against Ki-67 or serotonin, apart from a borderline negative correlation between PUFA and serotonin (r = -
0.3616, p = 0.0496).
Conclusion Lipid composition might provide a biomarker to study lymphovascular invasion in breast cancer.
Key Points
• Monounsaturated fatty acids in lymphovascular invasion (LVI) positive invasive breast carcinoma were significantly lower
than that in LVI negative.
• Triglycerides in LVI positive invasive breast carcinoma were significantly lower than that in LVI negative.
• Lipid composition from MR spectroscopy reflects the rate of de novo lipogenesis and provides a potential biomarker indepen-
dent from histological grade and stage.
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The 10-year survival rate in patients with breast cancer is
approximately 75% [1], despite the improved survival [1]
as a result of early detection, screening and new treat-
ments [2]. Lymphovascular invasion (LVI) is an impor-
tant histopathological feature of prognostic value indepen-
dent from histological grade [3] that correlates with pro-
liferative activity marker Ki-67 [4] and nodal status [5].
However, the full assessment of LVI is achieved at the
final histology [6] due to partial sampling error in pre-
operative biopsy [7]. Other factors including tissue
shrinkage (although immunohistochemistry might be used
to highlight endothelial cells) [8] and mechanical force–
induced cell displacement [9] can affect the assessment,
especially after tumour dissipation induced by neoadju-
vant chemotherapy can make histological assessment of
LVI difficult. LVI is associated with elevated risk of
lymph node metastasis [10] through tumour-associated
lymphangiogenesis [11], and the expression alterations
of genes in the incorporation of saturated- and monoun-
saturated fatty acids (SFA, MUFA) in phospholipid me-
tabolism [12]. Pro-inflammatory polyunsaturated fatty ac-
id (PUFA)–derived eicosanoids recruit macrophages to
trigger immune response leading to elevated serotonin
(5-HT) [13] that is associated with worse 10-year survival
[14]. Hence, non-invasive quantification of lipid compo-
sition as a marker of LVI has a potential role in
personalised care, especially in the context of neoadjuvant
treatment.
Lipid composition can be measured using biochemical ex-
traction methods for gas chromatography [15], but suffering
from invasiveness, labour-intensive procedures and high cost
[16]. Magnetic resonance spectroscopy (MRS) is a powerful
tool for non-invasive biochemical quantification with scan-
ners readily available in tertiary hospitals, but unable to dis-
cern lipid constituents due to overlapping signals on a one-
dimensional spectrum [17]. Localised correlation spectrosco-
py (L-COSY) is capable of discerning lipid constituents in
breast cancer on a two-dimensional spectral map [18], but
suffering from water contamination signal and limited accura-
cy resulted from dispersed peak pattern. Double quantum fil-
tering (DQF), utilising signal selection targeting specific dou-
ble bonds in molecular structure [19], effectively suppresses
contamination signal and creates focused spectral peak.
Hence, DQF-MRS can single out PUFA for high accuracy
quantification [17], necessary in tumour due to low PUFA
fraction, while DQF-COSY provides accurate quantification
of lipid composition [19].
We therefore hypothesise there is a difference in lipid com-
position derived from DQF-MRS and DQF-COSY between
LVI status, and is independent from cell division and inflam-
mation in breast cancer.
Materials and methods
We conducted a two-group cross-sectional study to quantify
lipid composition in whole tumours freshly excised from pa-
tients with breast cancer, with further comparison against his-
topathological findings (Fig. 1).
Study approval The study was approved by the North West -
Greater Manchester East Research Ethics Committee (REC
Reference: 16/NW/0032), and signed written informed con-
sent was obtained from the patients prior to entry into the
study.
Clinical procedure Thirty female patients (age 39–78) with
grade II or III invasive ductal carcinoma participated in the
study. Patients over the age of 18, undergoing a wide local
excision or mastectomy, and with a tumour size larger than
1 cm in diameter on mammography were eligible. Patients
with previous breast malignancies or patients who had neoad-
juvant chemotherapy or neoadjuvant hormonal therapy prior
to surgery were excluded. In total, 50 patients consented to be
included in the study from 53 consecutive patients in the
Breast Unit at Aberdeen Royal Infirmary. However, from
these 50 resected tumour specimens, 11 were not scanned
due to theatre delays and MRI scanner unavailability. A fur-
ther 9 tumour specimens were excluded due to lobular pheno-
type (n = 2), mixed phenotype (n = 5) or grade I (n = 2) on
final histopathological examination of the excised tumour.
Standard histopathological examination was performed to de-
termine tumour size, grade, LVI, lymph node metastasis, re-
ceptors and Nottingham Prognostic Index (NPI) [20]. Upon
full histological examination, there were 13 LVI negative and
17 LVI positive breast cancers. Immunostaining was conduct-
ed in a single batch for Ki-67 (Clone MIB-1, Dako, Dilution
1/100) and serotonin (Clone HTR1A, Thermo Fisher
Scientific, Dilution 1/500) including appropriate positive con-
trols, with immunostainer Ventana Benchmark XT with
Ultraview DAB Detection Kit (760-500) (Ventana Medical
Systems, Inc.), and assessed by a consultant pathologist. Ki-
67 was quantitatively assessed as percentage of positive nuclei
(0–100%) [21], while serotonin was semi-quantitatively
assessed using the H-score: Membranous staining was scored
as 0 for ‘no staining’, 1 + for ‘weak staining’, 2 + for ‘mod-
erate staining’ and 3 + for ‘strong staining’. The percentage of
cells at different staining intensities was determined by visual
assessment. The final score was calculated using the formula 1
× (% of 1 + cells) + 2 × (% of 2 + cells) + 3 × (% of 3 + cells)
[22].
Lipid composition The freshly excised tumour specimen with-
out formalin treatment was immediately transported to the
Aberdeen Biomedical Imaging Centre. The lipid composition
spectra were acquired from a single voxel snug fit to the
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tumour on a 3 T whole-body clinical MRI scanner (Achieva
TX, Philips Healthcare) using a 32-channel receiver coil for
high sensitivity detection and a body coil for uniform trans-
mission. PUFA spectrum was acquired using DQF-MRS se-
quence [17] with a repetition time (TR) of 1250 ms, echo time
(TE) of 130 ms, spectral editing frequency at 2.8 ppm, band-
width of 2000 Hz and 1024 points. Reference spectrum (con-
ventional MRS) without water suppression was acquired
using PRESS sequence [23] with TR/TE of 1250/130 ms.
Lipid spectral map was acquired using DQF-COSY sequence
[19], with TR of 552 ms, initial TE of 25 ms, a t1 increment of
1 ms, 256 increments, bandwidth of 1000 Hz and 256 points.
The acquisition durations were 10min 40 s for DQF-MRS and
9 min 45 s for DQF-COSY. Further details of the methodol-
ogy can be found in the Supplementary Material.
DQF-MRS and DQF-COSY are complementary methods
for lipid composition quantification, with respective strength.
DQF-MRS targets a single metabolite through the manipula-
tion of quantum states of coupled spins, with the resonance
frequency at 2.8 ppm and 5.3 ppm for PUFA [17]. The em-
ployment of the field gradient effectively eliminates back-
ground signals beyond target metabolite, while the binary na-
ture of quantum coherence pathway selection leads to a 50%
loss of the signal [17]. DQF-COSY and L-COSY are localised
derivatives from COSY for 2D spectroscopy to allow the
identification of molecular structures. L-COSY, without
DQF, suffers from overwhelming background signal and
broad spectral peak appearance [19]. DQF-COSY embeds
DQF component within COSY, allowing suppression of
uncoupled signal across the spectral domain and a sharp spec-
tral peak appearance. However, DQF-COSY only retains 25%
of the signal, as a consequence of the quantum coherence
pathway selection and the use of stimulated echo [19].
PUFA was quantified using DQF-MRS and conventional
MRS, demanding minimal discrepancies between the two ac-
quisitions for accuracy. Both acquisitions adopted PRESS se-
quence backbone [17, 23] with identical voxel localisation RF
pulse shape and field gradient strength for identical voxel
location, voxel profile and chemical shift displacement. Both
acquisitions also adopted identical receiver gain configuration
with a shared scanner setup procedure for comparable nomi-
nal values and minimal hardware variability.
Lipid constituents were calculated as a ratio of the corre-
sponding spectral peak against the methyl proton peak, with-
out the quantification of absolute concentration using estimat-
ed T1 and T2. PUFA, quantified as spectral peak amplitude at
5.3 pm from DQF-MRS, was referenced to 0.9 ppm from
conventional MRS, while all the other lipid constituents,
quantified as corresponding spectral peak volumes from
DQF-COSY, were referenced to (0.9, 0.9) ppm from DQF-
COSY. The PUFA peak at 5.3 ppm from DQF-MRS is spec-
trally edited through coupling peak at 2.8 ppm [17] equivalent
to the cross peak at (5.3, 2.8) ppm in DQF-COSY or 2.8 ppm
in conventional 1DMRS, with the ratio against methyl proton
Fig. 1 Study design. A two-group
cross-sectional study is shown in
a flow chart. Fifty-three female
breast cancer patients were found
to be eligible at initial screening.
Upon approach, three patients
declined participation and the rest
were consented to the study. After
wide local excision or
mastectomy, the freshly excised
tumour specimen was scanned on
a 3 T clinical MRI scanner to





examinations were conducted to
assess lymphovascular invasion
(LVI), Ki-67 and serotonin
expression and Nottingham
Prognostic Index (NPI). In total,
30 patients with invasive ductal
carcinoma (IDC), 13 with LVI
negative and 17 with LVI
positive, participated in the study
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proportional to PUFA fraction [24]. The unsaturated fatty
acids (UFA) at (2.1, 2.1) ppm fromDQF-COSY encompasses
PUFA andMUFA substrates manifested at (5.3, 2.8) ppm and
(5.3, 2.1) ppm respectively, with the ratio of UFA against
methyl proton negatively proportional to SFA fraction (SFA
= 1-UFA/methyl) [25, 26].
The peak amplitudes of PUFA (5.3 ppm) and methyl pro-
ton (0.9 ppm) were quantified using prior knowledge data-
bases [27] and AMARES algorithm [28] in the jMRUI soft-
ware (v3.0, TRANSACT) [29]. The peak volumes of UFA,
triglycerides (TRG) and MUFA were quantified at (2.1, 2.1)
ppm, (4.3, 4.3) ppm and (5.3, 2.1) ppm respectively. Lipid
spectral maps were quantified in the Felix software (v2007,
Accelrys Inc.), with zerofilling to 512 points and two-
dimensional sine bell apodisation [19].
Statistical analysisAll statistical analysis was performed in the
SPSS software (Release 23.0, SPSS Inc.). Normality was de-
termined on all the collected data using the Shapiro-Wilk test.
Mann-Whitney U tests were used for MUFA, SFA and TRG
while independent sample t test for PUFA (normally distrib-
uted) between LVI groups. Fisher’s exact tests were applied
for categorical variables (clinicopathological features).
Spearman’s correlation tests were performed between lipid
composition against proliferative activity marker Ki-67 and
serotonin, while Pearson’s correlation test between PUFA
and serotonin in the entire cohort. A p value < 0.05 was ac-
cepted as being statistically significant.
Results
The patient demographics are summarised in Table 1. There
were no significant differences in age and body mass index
(BMI) between groups. There were no significant differences
in tumour size, NPI or stage between groups.
There were significantly lower MUFA (z = 2.3470, p =
0.0189, Fig. 2a, Table 2) in LVI positive (median: 0.37, inter-
quartile range (IQR): 0.25–0.64) than LVI negative (0.63,
0.49–0.96). There were significantly lower TRG (z =
2.2810, p = 0.0226, Fig. 2b, Table 2) in LVI positive (1.32,
0.95–2.43) than LVI negative (2.5, 1.92–4.15). There was no
significant difference in SFA (p = 0.6009, Fig. 2c, Table 2)
between LVI negative (0.50, 0.36–0.57) and LVI positive
(0.53, 0.41–0.58). There was no significant difference in
PUFA (p = 0.1641, Fig. 2d, Table 2) between LVI negative
(0.013 ± 0.006) and LVI positive (0.010 ± 0.006).
There were no significant correlations between lipid com-
position against Ki-67 (Fig. 3, Table 2). There were no signif-
icant correlations between MUFA, TRG and SFA against se-
rotonin, but a borderline significant negative correlation be-
tween PUFA and serotonin (r = - 0.3616, p = 0.0496, Fig. 4,
Table 2).
Discussion
In this work, we found positive LVI in breast cancer associat-
ed with lower MUFA and triglycerides, but not with SFA or
PUFA. Lipid compositions were not correlated with serotonin
or proliferative activity marker Ki-67, apart from a borderline
negative correlation between PUFA and serotonin. Hence,
lipid composition in breast tumourmight be a potential marker
of LVI.
LVI positivity was negatively associated with MUFA and
TRG, but not SFA or PUFA. SFA, the main product of de
novo lipogenesis, showed no significant difference between
LVI status, indicating potential negative feedback to avoid
apoptosis [30] and impaired angiogenesis [31] arising from a
further increase in SFA. SFA, an essential building block for
cell structural growth, is tightly regulated in the endogenous
fatty acid metabolism [32]. Excess SFA palmitate inhibits the
mitochondrial phospholipid cardiolipin [30] and suppresses
the activity of cathepsin critical for the formation of new en-
dothelial cell-lined blood vessels and consequent cancer pro-
liferation [31]. Hence, the equal spread of SFA distribution in
LVI positive and LVI negative might indicate a common pro-
tective mechanism against lipotoxicity [30]. The increased
MUFA in negative LVI indicates an accelerated conversion
from excess SFA for membrane phospholipid synthesis [32]
and epidermal growth factor signalling [33], while a reduced
MUFA observed in positive LVI due to the export of SFA via
tumour cells crossing the lymphatic vasculature [11].
The reduced TRG in positive LVI indicates accelerated de
novo lipogenesis unconstrained from lipotoxicity mitigated
through SFA clearance via tumour cells crossing the lymphat-
ic vasculature. Triglycerides (TRG), occupying spectral peak
at (4.3, 4.3) ppm [18], typically maintain a constant ratio
against methyl proton since the ratio of head groups and meth-
yl groups in the TRG chains is fixed. However, TRG is broken
down into glycerides and fatty acids in tumours under lipolytic
enzyme overexpression [34], with the variation in observation
primarily attributed to the glycerides. The spectral peak at
(4.3, 4.3) ppm has low SNR in low-fat fraction tumours [35,
36] and the contamination signal from mono- and di-
glycerides at 3 T [24, 37] may affect experimental accuracy.
PUFA showed no association with LVI, indicating the deple-
tion of naturally low abundant PUFA for membrane synthesis
[17] remaining unresolved despite the potential import from
peri-tumoural adipocytes in positive LVI. Hence, lipid com-
position is associated with LVI through the amplification of de
novo lipogenesis and could impact on peri-tumoural adipo-
cyte lipid content [38].
Lipid composition did not show a significant correlation
against proliferative activity marker Ki-67, indicating no evi-
dence to support a direct link between lipids and tumour cell
divisionwithin the framework of this work. Lipid composition
did not show a significant correlation, apart from a borderline
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negative correlation in PUFA, against serotonin (5-HT), an
epigenetically identified marker of poor 10-year survival rate
[14]. Hence, serotonin primarily reflects the upregulation in
membrane synthesis [13] (more depleted PUFA [17]) induced
by environmental factors, rather than intrinsic aggressiveness
or rapid division of the tumour cells.
Lipid composition in the breast has been quantified using
MRS in the adipose tissue from both patients and healthy
volunteers. Conventional STEAM sequence has been used
for the quantification of lipid composition in breast adipose
tissue from patients at 3 T [39] and healthy volunteers at 7 T
[40]. L-COSY has been used to reveal elevated PUFA in
breast adipose tissue in BRCA1 gene mutations carriers com-
pared to healthy controls [18]. Spatially resolved MRS using
multiple gradient-echo imaging, an extension from the Dixon
method, revealed elevated peri-tumoural SFA and suppressed
Table 2 Lipid composition and histological markers Ki-67 and
serotonin in lymphovascular invasion (LVI) negative and positive
breast tumours. Correlation scores (Spearman’s rho and Pearson’s r) of
lipid composition, quantified in double quantum–filtered correlation
spectroscopy (DQF-COSY) and DQF magnetic resonance spectroscopy
(DQF-MRS), against Ki-67 and serotonin are also shown.
Monounsaturated, saturated fatty acids (MUFA, SFA) and triglycerides
(TRG) were quantified from DQF-COSY, while polyunsaturated FA
(PUFA) from DQF-MRS. The spread of lipid composition from DQF-
COSY and Ki-67 expression is non-normal and is reported as median and
interquartile range (IQR). Significant findings (p < 0.05) are marked by
‘*’
LVI group DQF-COSY DQF-MRS Histological markers
SFA MUFA TRG PUFA Ki-67 (%) Serotonin (0–300)
All (n = 30) 0.52 (0.36–0.58) 0.49 (0.37–0.69) 2.01 (1.18–2.99) 0.011 ± 0.007 16.6 (9.7–24.0) 107 ± 62
LVI negative (n = 13) 0.50 (0.36–0.57) 0.63 (0.49–0.96)a 2.5 (1.92–4.15) 0.013 ± 0.006 17.3 (11.6–29.1) 84 ± 48















Correlation (r/ρ-score, p value)
Ki-67 0.2254, 0.2312 0.3108, 0.1008 0.0621, 0.7445 0.2071, 0.2721
Serotonin - 0.1444, 0.4465 0.0212, 0.9129 0.1312, 0.4894 - 0.3616, 0.0496*
aMUFA from one LVI negative breast tumour was not quantifiable due to low signal-to-noise ratio, i.e., n = 12
Table 1 Clinical characteristics of patients. Descriptive statistics of
breast cancer patients with histopathological findings are shown for
each group and the entire cohort. Numbers are expressed as mean and
standard deviation (apart from Nottingham Prognostic Index where
median and interquartile range are shown), with pathological entries
expressed as number of positive observations
Characteristic All (n = 30) Lymphovascular invasion (LVI) p value
Negative (n = 13) Positive (n = 17)
Age (years) 61.1 ± 11.5 59.2 ± 12.6 62.6 ± 10.6 0.4375
Body mass index (BMI) 30.4 ± 6.4 31.2 ± 7.5 29.5 ± 5.4 0.5451
Tumour size (cm) 2.5 ± 0.8 2.4 ± 0.7 2.5 ± 0.8 0.6070
Nottingham Prognostic Index (NPI) 4.41 (3.62–4.56) 4.29 (3.62–4.50) 4.44 (3.70–4.60) 0.4764
Tumour features
pTNM Stage
I 5 3 2 0.628
II 25 10 15
Histological grade
II 15 6 9 1.000
III 15 7 8
Lymph node involvement 8 2 6 0.407
Oestrogen receptor (ER+) 22 8 14 0.242
Human epidermal growth factor receptor 2 (HER2+) 6 2 4 0.672
Triple-negative breast cancer (TNBC) 7 5 2 0.190
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Fig. 3 Scatter plots to show the
correlation of monounsaturated
fatty acids (MUFA) (n = 29) (a),
triglycerides (TRG) (n = 30) (b),
saturated FA (SFA) (n = 30) (c),
and polyunsaturated FA (PUFA)
(n = 30) (d) withKi-67 expression
within the entire cohort.
Spearman’s rank correlation tests
were performed and rho (ρ)
scores and p values are displayed.
There were no significant
correlations between MUFA,
TRG, SFA or PUFA with Ki-67
expression
Fig. 2 Dot plots to show the
group difference in
monounsaturated fatty acids
(MUFA) (n = 12, 17) (a),
triglycerides (TRG) (n = 13, 17)
(b), saturated FA (SFA) (n = 13,
17) (c) and polyunsaturated FA
(PUFA) (n = 13, 17) (d) between
LVI negative and LVI positive
breast tumours. The error bar
indicates the median and
interquartile range (mean ± SD
for PUFA). Mann-Whitney U
tests (a–c) and independent
sample t test (d) were performed
between the groups and p value is
shown for each plot. Statistically
significant p values (< 0.05) are
marked by an asterisk
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MUFA in postmenopausal patients compared to healthy con-
trols [41, 42]. However, the investigation of intra-tumoural
lipid composition has been limited to fat fraction owing to
low abundance of lipids inside breast tumour [43], with the
feasibility as a potential marker for response to chemotherapy
[35] and the identification of tumour subtypes [36] attempted.
The introduction of DQF-MRS allowed the observation of
substantially reduced PUFA in breast tumours [17], and this
work augmented the understanding of lipid composition in
breast cancer [44] using the most sensitive MRS approaches
through a formal clinical study on LVI.
This study is the first to investigate the association between
lipid composition and LVI positivity in whole human breast
tumours. The quantitative nature of the novel spectroscopy
method provides an objective approach for LVI evaluation,
compared to time-consuming and experience-dependent his-
tological approaches. The quantification at whole tumour es-
timates an overall degree of compromise in lymphatic vascu-
lature [11], eliminating partial sampling error inherent in bi-
opsy approaches (high false negative of 40% in this study
alone) [7]. The ex vivo study design allows the elimination
of biological noise and employment for accurate quantifica-
tion, particularly in the context of depleted PUFA and triglyc-
erides. The deployment of DQF approach suppresses contam-
ination signals proximal to PUFA and triglycerides in the
spectral domain, further enhancing quantification accuracy.
The feasibility of the employed MRS approaches for in vivo
application has been demonstrated using standard clinical
scanner, while the clinical utility with underpinning sensitivity
to critical tumour metabolic pathways has been shown as an
initial step in clinical translation. The lipid composition
coupled with current clinical dynamic contrast-enhanced
(DCE) and diffusion-weighted MRI may enhance the diag-
nostic accuracy to reduce false-positive rate.
SFA and TRG are determined from diagonal peaks, with
MUFA from cross peak, leading to a difference in scaling
from underlying population in energy states. Hence, the com-
parison is performed on individual lipid constituent across
patients, and comparison of nominal values between peaks
will require further correction on the scaling factors. The over-
lap of the distribution in MUFA or TRG between groups may
limit the diagnostic value of lipid composition as a biomarker
in LVI. This work, as a precursor for consequent in vivo pa-
tient studies, attempted to augment the understanding of lipid
composition in breast cancer with limited statistical power for
multiple comparison correction. Future large cohort in vivo
studies, supported by novel spectral analysis approaches [45],
are required to confirm the relationship between lipid compo-
sition and LVI. Further trials integrating the lipid composition
for treatment planning are critical, since neoadjuvant chemo-
therapy is more likely to be recommended for LVI positive
patients [46].
Fig. 4 Scatter plots to show the
correlation of monounsaturated
fatty acids (MUFA) (n = 29) (a),
triglycerides (TRG) (n = 30) (b),
saturated FA (SFA) (n = 30) (c)
and polyunsaturated FA (PUFA)
(n = 30) (d) with serotonin
expression within the entire
cohort. Spearman’s rank
correlation (a–c) and Pearson’s
correlation (d) tests were
performed and corresponding rho
(ρ) and r scores and p values are
displayed. Statistically significant
p values (< 0.05) are marked by
an asterisk
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In conclusion, MUFA and triglycerides are reduced in pos-
itive LVI resulting from accelerated de novo lipogenesis.
Lipid composition observed through novel spectroscopy
method might provide a biomarker to study LVI in breast
cancer.
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